Pamplona Therapeutics is a biotech developing targeted protein degradation (TPD) therapies to address unmet needs in autoimmune diseases. Pamplona has created a cutting-edge AI-driven TPD drug discovery platform. Utilizing this AI-driven platform, we have developed two PCCs within 18 months. Pamplona will file its first IND application in 2025. Subsequently, we aim to leverage our platform to tackle other undruggable targets and address a wide range of global disease threats.